Online inquiry

IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(unconjugated)(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ1763MR)

This product GTTS-WQ1763MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets IL2RA gene. The antibody can be applied in Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000417.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3559
UniProt ID P01589
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(unconjugated)(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ1763MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ621MR IVTScrip™ mRNA-Anti-IL9, 7F3com-2H2(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA 7F3com-2H2
GTTS-WQ13337MR IVTScrip™ mRNA-Anti-PDCD1, PF-06801591(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA PF-06801591
GTTS-WQ6789MR IVTScrip™ mRNA-Anti-ERBB2, DS-8201(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA DS-8201
GTTS-WQ5110MR IVTScrip™ mRNA-Anti-CD52, Campath-1H(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA Campath-1H
GTTS-WQ4969MR IVTScrip™ mRNA-Anti-GP, c2G4-N(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA c2G4-N
GTTS-WQ4129MR IVTScrip™ mRNA-Anti-ICAM1, BI-505(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA BI-505
GTTS-WQ1598MR IVTScrip™ mRNA-Anti-GDF11, ACE-536(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ACE-536
GTTS-WQ7048MR IVTScrip™ mRNA-Anti-VEGFA, Fab-12 variant Y0317(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA Fab-12 variant Y0317
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW